HIV感染患者血脂异常的管理。
Management of dyslipidemia in HIV-infected patients.
作者信息
Malvestutto Carlos D, Aberg Judith A
机构信息
Division of Infectious Diseases & Immunology, Bellevue Hospital Center, New York University School of Medicine, NY, USA.
出版信息
Clin Lipidol. 2011 Aug;6(4):447-462. doi: 10.2217/clp.11.25.
Abstract
Antiretroviral therapy has dramatically increased survival for HIV-infected individuals. As this population lives longer, coronary heart disease has become an important comorbid condition. Dyslipidemia in HIV-infected individuals is a complex condition, with multiple contributing factors including the HIV virus itself, individual genetic characteristics and antiretroviral therapy-induced metabolic changes. Effective management of dyslipidemia in this population is essential to reduce cardiovascular risk but presents multiple challenges due to interactions between antiretroviral therapy agents and lipid-lowering medications.
摘要
抗逆转录病毒疗法显著提高了艾滋病毒感染者的生存率。随着这一人群寿命的延长，冠心病已成为一种重要的合并症。艾滋病毒感染者的血脂异常是一种复杂的病症，有多种促成因素，包括艾滋病毒本身、个体遗传特征以及抗逆转录病毒疗法引起的代谢变化。有效管理这一人群的血脂异常对于降低心血管风险至关重要，但由于抗逆转录病毒治疗药物与降脂药物之间的相互作用，这带来了多重挑战。
相似文献
1
Management of dyslipidemia in HIV-infected patients.
Clin Lipidol. 2011 Aug;6(4):447-462. doi: 10.2217/clp.11.25.
2
Evaluation and management of dyslipidemia in patients with HIV infection.
J Gen Intern Med. 2002 Oct;17(10):797-810. doi: 10.1046/j.1525-1497.2002.20201.x.
3
Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons.
HIV Clin Trials. 2004 Nov-Dec;5(6):416-33. doi: 10.1310/P07M-HNT8-L08G-5TKU.
4
Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort.
Open AIDS J. 2008;2:26-38. doi: 10.2174/1874613600802010026. Epub 2008 Mar 24.
5
Management of metabolic complications and cardiovascular risk in HIV-infected patients.
AIDS Rev. 2010 Oct-Dec;12(4):231-41.
6
[HIV infection, antiretroviral therapy, and endothelium].
Herz. 2005 Sep;30(6):472-80. doi: 10.1007/s00059-005-2740-3.
7
Dyslipidemia and lipid management in HIV-infected patients.
Curr Opin Endocrinol Diabetes Obes. 2011 Apr;18(2):144-7. doi: 10.1097/MED.0b013e328344556e.
8
Managing dyslipidemia in HIV/AIDS patients: challenges and solutions.
HIV AIDS (Auckl). 2014 Dec 17;7:1-10. doi: 10.2147/HIV.S46028. eCollection 2015.
9
Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
Clin Infect Dis. 2000 Nov;31(5):1216-24. doi: 10.1086/317429. Epub 2000 Nov 7.
10
Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review.
Top HIV Med. 2006 Oct-Nov;14(4):134-9.
引用本文的文献
1
Optimizing statin therapy in HIV-infected patients: a review of pharmacotherapy considerations.
BMC Cardiovasc Disord. 2025 May 31;25(1):421. doi: 10.1186/s12872-025-04887-2.
2
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy.
J Antimicrob Chemother. 2025 Jul 1;80(7):1849-1859. doi: 10.1093/jac/dkaf137.
3
Apolipoprotein E genetic variation, atherogenic index and cardiovascular disease risk assessment in an African population: An analysis of HIV and malaria patients in Ghana.
PLoS One. 2023 May 3;18(5):e0284697. doi: 10.1371/journal.pone.0284697. eCollection 2023.
4
Subclinical Atherosclerosis Is Associated with Discrepancies in BAFF and APRIL Levels and Altered Breg Potential of Precursor-like Marginal Zone B-Cells in Long-Term HIV Treated Individuals.
Vaccines (Basel). 2022 Dec 30;11(1):81. doi: 10.3390/vaccines11010081.
5
The Incidence and Risk Factors of Renal Insufficiency among Korean HIV infected Patients: The Korea HIV/AIDS Cohort Study.
Infect Chemother. 2022 Sep;54(3):534-541. doi: 10.3947/ic.2022.0101.
6
Atherosclerosis in HIV Patients: What Do We Know so Far?
Int J Mol Sci. 2022 Feb 24;23(5):2504. doi: 10.3390/ijms23052504.
7
Immunosuppression and HIV Viremia Associated with More Atherogenic Lipid Profile in Older People with HIV.
AIDS Res Hum Retroviruses. 2019 Jan;35(1):81-91. doi: 10.1089/AID.2018.0145. Epub 2018 Nov 27.
8
Factors affecting high-density lipoprotein cholesterol in HIV-infected patients on nevirapine-based antiretroviral therapy.
Indian J Med Res. 2017 May;145(5):641-650. doi: 10.4103/ijmr.IJMR_1611_15.
9
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.
HIV AIDS (Auckl). 2017 Mar 3;9:51-61. doi: 10.2147/HIV.S108756. eCollection 2017.
10
Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study.
HIV AIDS (Auckl). 2016 Oct 25;8:165-174. doi: 10.2147/HIV.S113206. eCollection 2016.
本文引用的文献
1
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.
Clin Infect Dis. 2011 Apr 1;52(7):929-40. doi: 10.1093/cid/ciq244.
2
Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein.
J Intern Med. 2011 Feb;269(2):232-42. doi: 10.1111/j.1365-2796.2010.02323.x. Epub 2010 Dec 3.
3
Dyslipidemia and its Treatment in HIV Infection.
Top HIV Med. 2010 Aug-Sep;18(3):112-8.
4
European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142.
AIDS. 2011 Jan 2;25(1):37-47. doi: 10.1097/QAD.0b013e32833f9d02.
5
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.
J Clin Lipidol. 2010 Jul-Aug;4(4):279-87. doi: 10.1016/j.jacl.2010.04.003.
6
Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults.
AIDS. 2010 Jul 17;24(11):1727-31. doi: 10.1097/QAD.0b013e32833ac7be.
7
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. doi: 10.1097/HJR.0b013e328336a150.
8
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
AIDS. 2010 Jul 17;24(11):1781-4. doi: 10.1097/QAD.0b013e32833ad8b4.
9
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
J Acquir Immune Defic Syndr. 2010 Sep;55(1):39-48. doi: 10.1097/QAI.0b013e3181da1287.
10
Drug-drug interactions between raltegravir and pravastatin in healthy volunteers.
J Acquir Immune Defic Syndr. 2010 Sep;55(1):82-6. doi: 10.1097/QAI.0b013e3181d9a354.
Zotero 插件